MétaCan
Menu
Back to cohort
Record W3201723867 · doi:10.1177/13524585211049986

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

2021· article· en· W3201723867 on OpenAlexafffund
Michael Zhong, Anneke van der Walt, Jim Stankovich, Tomáš Kalinčík, Katherine Buzzard, Olga Skibina, Cavit Boz, Suzanne Hodgkinson, Mark Slee, Jeannette Lechner‐Scott, Richard Macdonell, Julie Prévost, Jens Kühle, Guy Laureys, Liesbeth Van Hijfte, Raed Alroughani, Allan G. Kermode, Ernest Butler, Michael Barnett, Sara Eichau, Vincent Van Pesch, Pierre Grammond, Pamela McCombe, Rana Karabudak, Pierre Duquette, Marc Girard, Bruce Taylor, Wei Zhen Yeh, Mastura Monif, Melissa Gresle, Helmut Butzkueven, Vilija Jokubaitis

Bibliographic record

VenueMultiple Sclerosis Journal · 2021
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsUniversité de MontréalCentre intégré de santé et de services sociaux de Chaudière-AppalachesCegep de Saint Jerome
FundersNovartis PharmaSanofi GenzymeEMD SeronoDokuz Eylül ÜniversitesiUniversity of TasmaniaMultiple Sclerosis Society of CanadaCanadian Institutes of Health ResearchTeva Pharmaceutical IndustriesBiogenCelgeneSanofi
KeywordsOcrelizumabMultiple sclerosisMedicineClinical neurologyInternal medicinePsychologyNeuroscienceImmunology

Abstract

fetched live from OpenAlex

Background: Increasingly, people with relapsing-remitting multiple sclerosis (RRMS) are switched to highly effective disease-modifying therapies (DMTs) such as ocrelizumab. Objective: To determine predictors of relapse and disability progression when switching from another DMT to ocrelizumab. Methods: Patients with RRMS who switched to ocrelizumab were identified from the MSBase Registry and grouped by prior disease-modifying therapy (pDMT; interferon-β/glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod or natalizumab) and washout duration (<1 month, 1–2 months or 2–6 months). Survival analyses including multivariable Cox proportional hazard regression models were used to identify predictors of on-ocrelizumab relapse within 1 year, and 6-month confirmed disability progression (CDP). Results: After adjustment, relapse hazard when switching from fingolimod was greater than other pDMTs, but only in the first 3 months of ocrelizumab therapy (hazard ratio (HR) = 3.98, 95% confidence interval (CI) = 1.57–11.11, p = 0.004). The adjusted hazard for CDP was significantly higher with longer washout (2–6 m compared to <1 m: HR = 9.57, 95% CI = 1.92–47.64, p = 0.006). Conclusion: The risk of disability worsening during switch to ocrelizumab is reduced by short treatment gaps. Patients who cease fingolimod are at heightened relapse risk in the first 3 months on ocrelizumab. Prospective evaluation of strategies such as washout reduction may help optimise this switch.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.009
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.414
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.009
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0010.000
Scholarly communication0.0000.001
Open science0.0000.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.178
GPT teacher head0.308
Teacher spread0.130 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations16
Published2021
Admission routes2
Has abstractyes

Explore more

Same venueMultiple Sclerosis JournalSame topicMultiple Sclerosis Research StudiesFrench-language works237,207